51.99 0 (0%) | 10-19 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 60.73 | 1-year : | 70.93 |
Resists | First : | 52 | Second : | 60.73 |
Pivot price | 51.99 | |||
Supports | First : | 51.95 | Second : | 51.93 |
MAs | MA(5) : | 51.99 | MA(20) : | 51.99 |
MA(100) : | 44.6 | MA(250) : | 33.93 | |
MACD | MACD : | 0.1 | Signal : | 0.1 |
%K %D | K(14,3) : | 50 | D(3) : | 50 |
RSI | RSI(14): 79.1 | |||
52-week | High : | 52 | Low : | 14.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CCXI ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 52.05 - 52.3 | 52.3 - 52.52 |
Low: | 51.36 - 51.66 | 51.66 - 51.92 |
Close: | 51.55 - 52.01 | 52.01 - 52.4 |
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Mon, 25 Mar 2024
ChemoCentryx: 3Q Earnings Snapshot - Yahoo Movies Canada
Sun, 24 Mar 2024
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA - Yahoo Movies Canada
Sun, 10 Mar 2024
Should You Buy ChemoCentryx (CCXI) Ahead of Earnings? - Yahoo Movies UK
Thu, 20 Oct 2022
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX - PR Newswire
Tue, 18 Oct 2022
ChemoCentryx shareholders approve $3.7B merger with Amgen (NASDAQ:CCXI) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 70 (M) |
Shares Float | 59 (M) |
Held by Insiders | 12 (%) |
Held by Institutions | 79.7 (%) |
Shares Short | 6,560 (K) |
Shares Short P.Month | 5,640 (K) |
EPS | -0.94 |
EPS Est Next Qtrly | -0.32 |
EPS Est This Year | -0.9 |
EPS Est Next Year | -1.37 |
Book Value (p.s.) | 5.17 |
Profit Margin | 0 % |
Operating Margin | -508 % |
Return on Assets (ttm) | -18.5 % |
Return on Equity (ttm) | -45.4 % |
Qtrly Rev. Growth | -47.3 % |
Gross Profit (p.s.) | -0.73 |
Sales Per Share | 0.39 |
EBITDA (p.s.) | -1.93 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -45 (M) |
Levered Free Cash Flow | -55 (M) |
PE Ratio | -55.31 |
PEG Ratio | 0 |
Price to Book value | 10.03 |
Price to Sales | 133.21 |
Price to Cash Flow | -80.52 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |